News On Projects
Products & Services
Projects Database
Tenders Database
E - Newsletter
EPXonline.com
Project Financing
Contracts & Awards
Energy
Electricity
Mining
Oil & Gas
Infrastructure
Airport
Port
Railway
Road
Freezone
Construction
Manufacturing
Cement
Engineering
Automobile
Plastic
Metal
Textile
Paper & Packaging
Leather
Sugar
Edible Oil
Electrical & Electro
Processing
Chemical
Drugs & Pharma
Fertiliser
I-C-T
Communication
IT
Telecom
Water
Pump Station
Water Treatment
Water Supply
Hospitality
Hotel
Restaurant
Resort
Entertainment
Sports
Multiplex
Theme Park
Food & Beverages
Hospital
Service
Social
Science
Irrigation
Government
Policy
Economic Indicators
Company News
Commerce
Miscellaneous
News Uploaded On : Wednesday, August 19, 2015 1:16:00 PM IND Back  |  Latest Projects  |  Latest Tenders
 
 E-mail this to a friend        Printable version       Story Viewed 32858 Times
Aurobindo Pharma to build three formulation plants in Andhra Pradesh, Telangana.
Drug maker Aurobindo Pharma Ltd recently said it is planning to scale up its capacity as it expects more launches in its key US market and also plans to make India its sourcing hub for its Western European generic drug business that it had acquired from Actavis Plc.

The Hyderabad-based company said it will set up three new plants in Andhra Pradesh and Telangana over the next 12 months and will also ramp up the capacity of the existing ones.

It has began work on three new projects that include oral solid finished dosages facility at Naidupet in Nellore district (Andhra Pradesh), oral finished dosage facility for European markets in Visakhapatnam (Andhra Pradesh) and new semi-synthetic penicillin plant at Jadcherla, near Hyderabad (Telangana).

The three new projects will be part of Aurobindo’s Rs.900 crore proposed capital expenditure plan for this financial year. All expansions and new projects will partly go live in 2015-16 and the balance in 2016-17, the company said in its annual report.

“The capacity building efforts are to provide further opportunities for the existing products, cater to a growing product portfolio, as well as to service the Western European markets,” managing director N. Govindarajan said.

“Amongst peers, Aurobindo has emerged as one of the top abbreviated new drug application (ANDA) filers,” said Sarabjit Kour Nangra, pharma sector analyst with brokerage Angel Broking Ltd.

He said the company has aggressively filed ANDAs in the last few years. It is now geared to reap benefits even though most of the filings are for highly competitive products,” Nangra said.

Aurobindo has filed 379 ANDAs until 30 June, of which around half of them were filed in 2014 and 2015.

In January last year, Aurobindo bought loss-making commercial operations of Irish multinational drug maker Actavis for €30 million and US-based nutritional supplement maker Natrol Inc. for $132.5 million in a bankruptcy auction.

As part of its turnaround plan for Actavis, Aurobindo is taking advantage of its low-cost manufacturing base in India, along with launching its own product range in the injectibles and generics segments. “The objective is to optimize on costs while enlarging volume and value,” Govindarajan said.

The drug maker said it is developing 15 products for it oncology segment, and is planning a potential launch in 2017-18.

Livemint

Post your comments:

Your name: *
E-Mail Id:
E-mail ID will not be published
Comment: *
Maximum 500 Characters
    
Related Stories
China’s Fosun bids to buy India’s Gland Pharma.
Alembic Pharma forms JV with Orbicular for derma products.
Rusan Pharma aims to double turnover to Rs 600 cr by 2018
Indoco Remedies shares soar 19% on USFDA nod for Goa plant.
GSK Pharma plans Rs. 500-cr expansion of its Nashik unit.
Mankind Pharma to invest Rs. 150 crore in Paonta Sahib plant.
Green panel okays Aurobindo Pharma's Telangana unit expansion.
GSK begins work on new factory to make tablets and capsules.
IICT promises to assist pharma industry in AP.
IDPL modernises tablet making unit at Gurgaon plant.
RELATED PROJECTS & TENDERS
ADVERTISEMENT
MOST POPULAR STORIES NOW
For all enquiries please contact
Tel: 022 - 25961254, 25960909
Mobile: 9821464666/09751178830
Mail: marketing@newsonprojects.com

OUR OTHER PRODUCTS & SERVICES:    Projects Database   |   Project e-Newsletter   |   Tenders Database   |   Commissioned Power Plants   |   Company Index
About Us   |   Contact Us   |   Terms of Use   |   Advertise with Us   |   Privacy Policy   |   Disclaimer   |   Feedback